Compositions and methods to affect skin irritation
First Claim
Patent Images
1. A method for reducing skin irritation and/or reducing skin inflammation and/or reducing irritant-induced IL-1α
- secretion induced by a topical agent comprising topically applying a composition comprising;
(a) an amount of at least one topical irritating agent that causes skin irritation and/or skin inflammation and/or IL-1α
secretion, wherein the at least one topical irritating agent comprises a retinoid, a retinoid derivative, or a retinoid precursor, wherein the retinoid, retinoid derivative and the retinoid precursor are selected from the group consisting of retinol, retinal, retinyl esters, tretinoin, retinoic acid, Vitamin A, an ester of Vitamin A, isotretinoin, alitertinoin, etretinate, acitretin, adapalene, bexarotene, and tazarotene, and combinations thereof; and
(b) an amount of at least one chitosan covalently modified with octane sulfonic acid via a sulfonamide linkage.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions are described that contain treated chitosan, modified chitosan and/or modified and treated chitosan for use in formulations for skin, hair and nails, and in compositions and methods of reducing topical agent-induced skin irritation and inflammation.
-
Citations
7 Claims
-
1. A method for reducing skin irritation and/or reducing skin inflammation and/or reducing irritant-induced IL-1α
- secretion induced by a topical agent comprising topically applying a composition comprising;
(a) an amount of at least one topical irritating agent that causes skin irritation and/or skin inflammation and/or IL-1α
secretion, wherein the at least one topical irritating agent comprises a retinoid, a retinoid derivative, or a retinoid precursor, wherein the retinoid, retinoid derivative and the retinoid precursor are selected from the group consisting of retinol, retinal, retinyl esters, tretinoin, retinoic acid, Vitamin A, an ester of Vitamin A, isotretinoin, alitertinoin, etretinate, acitretin, adapalene, bexarotene, and tazarotene, and combinations thereof; and(b) an amount of at least one chitosan covalently modified with octane sulfonic acid via a sulfonamide linkage. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- secretion induced by a topical agent comprising topically applying a composition comprising;
Specification